Literature DB >> 22112319

Evolving standards of care in advanced gastric cancer.

Jean-Emmanuel Kurtz1, Patrick Dufour.   

Abstract

Despite its decreasing incidence in western countries, the care of gastric cancer remains a concern, as many patients are diagnosed with advanced disease. Whereas localized gastric cancer has benefited from advances in surgical management and perioperative chemotherapy, patients with unresectable or metastatic disease have a poor prognosis. However, advances in chemotherapy have still arisen, with the onset of more convenient and active schedules of treatment, but no significant breakthrough has been achieved in terms of survival. Recent trials in advanced gastric cancer have been focusing on targeted therapies. This article aims to focus on the current state of the art in terms of chemotherapy for advanced gastric cancer, as well as to describe and explain the rationale and hopes for newer therapies that are currently under investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112319     DOI: 10.2217/fon.11.115

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.

Authors:  Kong-Kong Wei; Lei Jiang; Yao-Yao Wei; Yu-Feng Wang; Xuan-Kun Qian; Qiang Dai; Quan-Lin Guan
Journal:  Tumour Biol       Date:  2014-05-29

2.  RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice.

Authors:  Jibin Yao; Mingxu Da; Tiankang Guo; Yaoxing Duan; Yongbin Zhang
Journal:  Tumour Biol       Date:  2013-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.